Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, China Pharma Holding's enterprise value is €43.38 Mil.
China Pharma Holding's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.17 Mil. Therefore, China Pharma Holding's EV-to-EBITDA for today is -37.04.
The historical rank and industry rank for China Pharma Holding's EV-to-EBITDA or its related term are showing as below:
STU:XQJ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2183.08 Med: -3.9 Max: 1085.56
Current: -36.79
During the past 13 years, the highest EV-to-EBITDA of China Pharma Holding was 1085.56. The lowest was -2183.08. And the median was -3.90.
STU:XQJ's EV-to-EBITDA is ranked worse than 100% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.305
vs STU:XQJ: -36.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
China Pharma Holding (STU:XQJ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Pharma Holding's PE Ratio (TTM) for today is calculated as:
China Pharma Holding's share price for today is €26.80.
China Pharma Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.282.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for China Pharma Holding's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:XQJ vs INCR, TLPH, CTOR: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's EV-to-EBITDA falls into.
China Pharma Holding's current Enterprise Value is €43.38 Mil.
China Pharma Holding's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (STU:XQJ) has a EV-to-EBITDA of -37.04 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Pharma Holding. According to the industry distribution chart, China Pharma Holding ranks #999999 out of 736 companies in the Drug Manufacturers industry.
Is China Pharma Holding's EV-to-EBITDA too high?
China Pharma Holding's current EV-to-EBITDA is -37.04. Based on the distribution chart, China Pharma Holding ranks #999999 out of 736 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Pharma Holding has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's EV-to-EBITDA compare to INCR and TLPH?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #999999 out of 736 companies for EV-to-EBITDA. This places China Pharma Holding in the lower half of its industry. The industry median EV-to-EBITDA is 13.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.31, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Pharma Holding. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current EV-to-EBITDA is -37.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current EV-to-EBITDA of -37.04. The stock's GF Value™ is €4.22, compared to a current price of €26.80 — trading 535.1% above its estimated fair value. The current EV-to-EBITDA is -37.04. China Pharma Holding's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current EV-to-EBITDA is -37.04 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (STU:XQJ) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of €26.80 is trading 535.1% above its estimated GF Value™ of €4.22.
Key valuation signals for STU:XQJ:
EV-to-EBITDA: -37.04
GF Value™: €4.22 vs. price of €26.80 (535.1% above fair value)
No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
33GF Score
Get the complete analysis for STU:XQJ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XQJ has been successfully added to your 
